\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationOnline
ProgrammesThe Horizon Europe Cluster 1 Health Info Day is organised by the European Commission to provide (prospective) applicants the opportunity to familiarise with the topics under the 2024 work programme and raise questions.
Please note that the Commission encourages participants to watch the pre-recorded presentations ahead of the event. These pre-recorded presentations will appear on the Commission website shortly. You can send your questions in advance via Sli.do by using #CL1INFODAY.
More information, the detailed programme and registration on the Commission website.
The Commission Info Day will be followed by a Brokerage event on 2 June 2023, organised by the Horizon Europe Cluster 1 National Contact Points through HNN3.0 initiative. This will complement the Info Day with an offer of matchmaking opportunities to prospective applicants to support the building of consortia.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
